GILD
Gilead Sciences Inc.
Is GILD Halal?
Antiviral and other medicines are generally permissible, but March 2026 debt exceeds the examined one-third total-assets financial limit.
What You Should Know
Gilead develops antiviral, oncology and other medicines, including treatments for HIV and hepatitis, so the core life-preserving activity remains generally permissible. Its March 31, 2026 filing shows debt at 39.40% of total assets, identifiable liquidity at 15.33%, receivables plus cash at 21.98%, and interest income at 1.36% of quarterly revenue. Product formulation, licensing and collaboration details do not support an exact prohibited-revenue percentage.
⚠️ Concerns
- •Debt was 39.40% of total assets at March 31, 2026 and exceeds the examined 33.333% limit
- •Interest income was 1.36% of quarterly revenue
- •Product ingredients, clinical research, pricing, access, patents, licensing, government contracts and manufacturing ethics require qualitative review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
22,174 / 56,278
8,626 / 56,278
12,369 / 56,278
95 / 6,960
- Financial
- Fails
- Overall
- Fails
Debt/assets is 39.40%, above the examined 33.333% limit; liquidity/assets is 15.33%, receivables plus cash/assets is 21.98%, and disclosed interest income is 1.36%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 39.40%, above the examined 33.33% total-assets limit; liquidity and receivables plus cash pass. This is not an index-membership claim.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 39.40%, above the examined 33% financial limit; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Gilead develops antiviral, HIV, hepatitis, oncology and other medicines. Life-preserving healthcare activity is generally permissible, while product and licensing details require evidence-based review.
Limitation: The filing does not provide a universal prohibited-revenue numerator by formulation, excipient, animal-derived input, indication, contract or licensing arrangement.
Purification
Disclosed interest income is 1.36% of quarterly revenue, but product-level screened business revenue remains unavailable; no fixed purification percentage is prescribed.
Inputs, assumptions and primary sources
- Amounts are USD millions from Gilead's March 31, 2026 Form 10-Q.
- Debt includes current portion of long-term debt of $1,313 million and long-term debt of $20,861 million.
- Cash is $7,628 million. Short- and long-term marketable debt securities total $998 million; equity and other investments are excluded.
- Net accounts receivable is $4,741 million and quarterly revenue is $6,960 million.
- Disclosed interest income is $95 million for the quarter.
- Gilead reports product, royalty, contract and other revenue but does not classify every formulation, ingredient, indication, license or collaboration as a reproducible prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →